Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China

Realtime	Geld	Brief	Zeit
	7,710	7,740	17:24
	7,704	7,742	17:24

Realtime

Geld

Brief

Zeit

7,710

7,740

17:24

7,704

7,742

17:24

Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China

WASHINGTON (dpa-AFX) - Theravance Biopharma, Inc. (TBPH) announced that Viatris Inc. has secured regulatory approval from China's National Medical Products Administration for YUPELRI inhalation solution, the first once-daily nebulized long-acting muscarinic antagonist approved for maintenance treatment of chronic obstructive pulmonary disease in China.

The approval triggers a one-time $7.5 million milestone from Viatris to Theravance, which is expected to be received in third quarter, 2025. Theravance Biopharma is also eligible for further sales-based milestones of up to $37.5 million and tiered royalties of 14% to 20% on net sales in China.

For More Such Health News, visit rttnews.com.

Copyright(c) 2025 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

Die USA haben fertig! 5 Aktien für den China-Boom

Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!

Hier klicken

Zeit	Aktuelle Nachrichten
13:06	Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China	WASHINGTON (dpa-AFX) - Theravance Biopharma, Inc. (TBPH) announced that Viatris Inc. has secured regulatory approval from China's National Medical Products Administration for YUPELRI inhalation... ► Artikel lesen
13:06	Theravance higher as China approves Viatris-partnered COPD therapy
12:18	China approves Theravance's YUPELRI for COPD treatment
12:05	Theravance Biopharma, Inc. - 8-K, Current Report
06.06.	Theravance and Mylan settle patent dispute with Eugia Pharma

Zeit

Aktuelle Nachrichten

13:06

Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China

13:06

Theravance higher as China approves Viatris-partnered COPD therapy

12:18

China approves Theravance's YUPELRI for COPD treatment

12:05

Theravance Biopharma, Inc. - 8-K, Current Report

06.06.

Theravance and Mylan settle patent dispute with Eugia Pharma

Zeit	Aktuelle Nachrichten
14:06	Viatris Reports Positive Data From Presbyopia Study	WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus... ► Artikel lesen
13:06	Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China	WASHINGTON (dpa-AFX) - Theravance Biopharma, Inc. (TBPH) announced that Viatris Inc. has secured regulatory approval from China's National Medical Products Administration for YUPELRI inhalation... ► Artikel lesen
13:06	Theravance higher as China approves Viatris-partnered COPD therapy
12:55	Viatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia	MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety... ► Artikel lesen
Di	Is Viatris Stock Underperforming the S&P 500?

Zeit

Aktuelle Nachrichten

14:06

Viatris Reports Positive Data From Presbyopia Study

WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus...
► Artikel lesen

13:06

Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China

13:06

Theravance higher as China approves Viatris-partnered COPD therapy

12:55

Viatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety...
► Artikel lesen

Is Viatris Stock Underperforming the S&P 500?

Unternehmen / Aktien	Kurs	%
THERAVANCE BIOPHARMA INC	9,350	+2,75 %
VIATRIS INC	7,626	-0,37 %

Unternehmen / Aktien

Kurs

THERAVANCE BIOPHARMA INC

9,350

+2,75 %

VIATRIS INC

7,626

-0,37 %

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche